Study: Many surrogate markers used for pivotal trials of products to treat non-oncologic chronic diseases lack meta-analyses linking them to outcomes, raising uncertainty of their validity Joshua D. Wallach Yale_CRRIT raps.org/news-and-artic…

📣 PROMPT LIPID trial is out!

✅ EHR-based decision support tools promote guideline-concordant, high-value, quality care for patients with very high risk ASCVD

Check out our editorial 🔥 Johns Hopkins Ciccarone Center Johns Hopkins Cardiology Jelani K. Grant Seth Martin

ahajournals.org/doi/10.1161/CI…

Happy to share our review on single pill combination therapy for treatment of hypertension #antoniococa #miguelcamafort Jose Patricio Lopez Lopez Seamus Whelton UW Cardiology Johns Hopkins Ciccarone Center Daichi Shimbo MD Stephen Juraschek MD, PhD, FAHA, AHSCP-CHS European Journal of Internal Medicine
sciencedirect.com/science/articl…

Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial @YaleHFdoc Kamil Faridi MD MSc Nimish Shah, MD Ralph J. Riello III, PharmD, BCPS Sanchit Kumar #AHAJournals ahajournals.org/doi/abs/10.116…

Consensus statement on colchicine in CAD from BIDMC Cardiovascular Division, put together by Lauren Balkan - a result of a lively discussion at our regular Clinical Consensus Conference at BIDMC CVI BIDMC CV Fellowship

Heart disease in women m.yale.edu/cjms via @yalemed A must read. This article captures the many layers of why so many women go underdiagnosed and undertreated for heart disease. Thank you Rachel Tompa samitshahmd Yuan Lu & Lisa Freed Yale Cardiology

Astonishing results from the DanGer Shock Trial presented at #ACC24 and out in NEJM today.

In patients with ST-elevation MI with cardiogenic shock, Impella reduced all-cause mortality (45.8% Impella vs. 58.5% control) at 180 days.

Some thoughts on this ground breaking trial:

Great teamwork for ⁦⁦American College of Cardiology⁩ Presentation led by ⁦The Osler Medical Residency⁩ Legends Kamil Faridi MD MSc⁩ & ⁦Erin D. Michos, M.D.⁩ - team work between ⁦Yale SOM⁩ ⁦Johns Hopkins Ciccarone Center⁩ ⁦Johns Hopkins Cardiology⁩ ⁦Johns Hopkins Medicine⁩

🌟 Excited to share our latest research at #ACC24 ! 🌟

Exploring Lipid Profiles & Therapy in AMI Patients without prior ASCVD.
Analyzing Medicare Spending on Key Drugs under the Inflation Reduction Act.
Delving into Lipid-lowering Therapy & LDL-C in patients with previous ASCVD.

Excited for #ACC24 ?
Visit NasirLab Houston Methodist CV prevention team presentations & share ur feedback
-Burden, variability and national/health system impact of CV metabolic risk
-CV impact of exposome measurements
- Insights on Cardiorhum & novel atheromeasurement in gen pop

Come catch a discussion of #SouthAsianCVD at #ACC24 on Monday April 8th from 12:45p-2p Excited to discuss with
Anandita Agarwala Kulkarni, MD FACC Dinesh Kalra, MD Jaideep Salim Virani Aarti M Thakkar and others!

Catch us there!
OurHealth Pradeep Natarajan Douglas Drachman Ami Bhatt, MD

It's time to rethink our approach to anabolic steroids & treat it with the same seriousness as other drug addictions.

It’s so common, it can no longer be ignored.

In American College of Cardiology, we outline typical steroid regimens & a strategy to guide users to safety.

bit.ly/3J05XJ4

82% of the EU’s farm subsidies go to animal-based foods that make up 84% of EU’s food-related GHGs yet supply just 35% of their calories.

This makes animal-rich foods artificially cheap & externalized impacts to taxpayers.

nature.com/articles/s4301…
drive.google.com/file/d/11gq41x…

When it comes to the prevention of cardiovascular disease I aways say, start early. People often ask, how early?

I say…From womb to tomb and from lust to dust.

A 🧵

A focused update to the 2019 NLA scientific statement on use of lipopr... sciencedirect.com/science/articl…. Updated guidance - Measured Lp(a) at least once in all adults! National Lipid Association Marlys Koschinsky Michael Boffa Dave Dixon, Professor & Chair @VCUPharmacy Keith C. Ferdinand, MD, FACC, FAHA, FNLA Erin D. Michos, M.D. Dan Soffer

My non-Lp(a) CV risk factors are optimally controlled, but because of my Lp(a) level, I still carry a 15.9% lifetime ASCVD risk. #KnowYourNumbers

SBP 110
LDL-c 40 / ApoB 47
No smoking
No drinking
Exercise nearly every day
Probably could improve sleep
BMI 22
A1c 4.9%

Planting the seed for blood pressure control! Excited to share our review on dietary prevention and management of hypertension 🌱🍓🥑🍍🥦💜

link.springer.com/article/10.100…

Rob Ostfeld, MD, MSc Dr. Michelle McMacken Kim Williams Clyde Yancy, MD, MSc American College of Cardiology American Heart Association

I appreciated the opportunity to contribute to the American Heart Association's Centennial collection.

Also, to think about AI in cardiovascular care, now & in the future, with brilliant colleague Jenna Wiens University of Michigan

Out in Circ: CQO:
ahajournals.org/doi/10.1161/CI…

CarDS Lab

Excited to share our latest collaboration from the MASALA Study led by the real #ViratKohli of #cvPrev Vardhmaan Jain 🏏 & Mahmoud Al Rifai 🧙‍♂️ assessing the association of Life’s Simple 7 CVH metrics with CAC incidence & progression in #SouthAsians

🔗 sciencedirect.com/science/articl…

Association of 🫀 health with subclinical coronary atherosclerosis progression among 5 racial & ethnic groups: MASALA & MESA studies - led by Drs. Vardhmaan Jain & ⁦Jaideep⁩ ⁦Emory Cardiology⁩ ⁦Johns Hopkins Ciccarone Center⁩ ⁦Johns Hopkins Cardiology⁩ sciencedirect.com/science/articl…